Over the past couple of weeks, we've been considering poorlyregarded stocks that have delivered outstanding returns over a 30-day period. We're back again today to look at another collection of lowly outperformers. Have these dogs had their day, or should you jump on the bandwagon, hoping to profit from the upward momentum?
Here are this week's magnificent seven, as identified by our new Motley Fool CAPS investment research service. Each of the companies below had been given a one-star rating (the lowest) by our community of investors just 30 days ago:
|
Stock |
30-day return |
One-year return |
|---|---|---|
|
Discovery Laboratories (NASDAQ:DSCO) |
42.18% |
-48.10% |
|
SIRVA (NYSE:SIR) |
41.06% |
-50.07% |
|
Foxhollow Technologies (NASDAQ:FOXH) |
30.99% |
-14.07% |
|
Realogy (NYSE:H) |
24.94% |
N/A |
|
Cephalon (NASDAQ:CEPH) |
24.74% |
56.89% |
|
Oceaneering International (NYSE:OII) |
24.14% |
61.75% |
|
Medis Technologies (NASDAQ:MDTL) |
23.45% |
45.28% |
Despite this impressive performance, four of the seven remain one-star stocks. Three of them, however, have earned a promotion. Cephalon, an international biopharmaceutical company, has since been bumped up to three stars, while both Realogy (a relocation company) and Oceaneering International (a provider of technical services for offshore activities) have earned another star.
Earlier this year, TMFBreakerBrian noted that Cephalon had so many shots on goal that some of them will likely score. As for Realogy, the Cendant spinoff has earned an outperform rating from all seven of the CAPS All-Star players who have rated it. Oceaneering International also earns unanimous approval from our All-Stars, with eight of eight giving it the thumbs-up. Apparently, ongoing oil-drilling activities in the Gulf are considered a catalyst by some in this group.
Is this information alone enough for you to take a flier on one of these stocks? Of course not. But they might be excellent candidates for further due diligence. In the meantime, get in the game and make your voice heard. You'll also be able to read timely analysis from our community, and perhaps offer your own pitch for one of these stocks. It's entirely free, and it's one of the few places I know where the expression "the more the merrier" is actually true.
Fool editor John Reeves does not own shares in any of the companies mentioned. Cendant was a former Inside Value pick. The Fool isinvestors writing for investors.
